Investigational Drug Information for Savolitinib
✉ Email this page to a colleague
What is the development status for investigational drug Savolitinib?
Savolitinib is an investigational drug.
There have been 34 clinical trials for Savolitinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 31st 2021.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, and Carcinoma. The leading clinical trial sponsors are AstraZeneca, Hutchison Medipharma Limited, and Parexel.
There are fourteen US patents protecting this investigational drug and two hundred and ninety-four international patents.
Summary for Savolitinib
| US Patents | 14 |
| International Patents | 294 |
| US Patent Applications | 82 |
| WIPO Patent Applications | 103 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2021-08-31) |
| Vendors | 42 |
Recent Clinical Trials for Savolitinib
| Title | Sponsor | Phase |
|---|---|---|
| Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment | Samsung Medical Center | Phase 2 |
| A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects | Parexel | Phase 1 |
| A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects | AstraZeneca | Phase 1 |
Clinical Trial Summary for Savolitinib
Top disease conditions for Savolitinib
Top clinical trial sponsors for Savolitinib
US Patents for Savolitinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Savolitinib | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Savolitinib | ⤷ Sign Up | Compounds and methods for inhibiting JAK | Dizal (Jiangsu) Pharmaceutical Co., Ltd. (Wuxi, Jiangsu Province, CN) | ⤷ Sign Up |
| Savolitinib | ⤷ Sign Up | Tank-binding kinase inhibitor compounds | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Savolitinib | ⤷ Sign Up | Compounds and methods for inhibiting JAK | Dizal (Jiangsu) Pharmaceutical Co., Ltd. (Wuxi, CN) | ⤷ Sign Up |
| Savolitinib | ⤷ Sign Up | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Savolitinib | ⤷ Sign Up | PD-1/PD-L1 inhibitors | Gilead Sciences, Inc. (Foster City, CA) | ⤷ Sign Up |
| Savolitinib | ⤷ Sign Up | Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile | Loxo Oncology Inc. (Stamford, CT) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Savolitinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Savolitinib | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Savolitinib | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Savolitinib | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| Savolitinib | European Patent Office | EP3452003 | 2036-05-05 | ⤷ Sign Up |
| Savolitinib | European Patent Office | EP3981392 | 2036-05-05 | ⤷ Sign Up |
| Savolitinib | Hong Kong | HK1249728 | 2036-05-05 | ⤷ Sign Up |
| Savolitinib | Japan | JP2019520866 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
